SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ONXX
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (281)4/8/1999 12:17:00 AM
From: scaram(o)uche  Read Replies (1) of 810
 
"A Phase II Trial of ONYX-015, a Selectively
Replicating Adenovirus, in Combination with Cisplatin
and 5-Fluorouracil in Patients with Recurrent Head and
Neck Cancer"

Oral Presentation:
Head and Neck Cancer
Date:
"May 16, 1999"
Time:
1:00 PM - 3:00 PM
Location:
202E

Preliminary Report: Adenovirus ONYX-015
Administered by Mouthwash as a Chemopreventative
Agent and for the Treatment of Oral Dysplastic Lesions

General Poster
Session:
Biological Therapy
Date:
"May 18, 1999"
Time:
8:00 AM - 12:00 PM
Location:
Hall C (East Wing)

A Phase I Study of Multiple Direct Injections of
Onyx-015 Adenovirus into Pancreatic Carcinomas
Under Endoscopic Ultrasound Guidance

General Poster
Session:
Clinical Pharamacology
Date:
"May 16, 1999"
Time:
1:00 PM - 5:00 PM
Location:
Hall C (East Wing)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News